SCHEMBL2537405

SCHEMBL2537405

Nc1cc(Cl)cc(C(=O)O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 3/20 0.70
HCAR1 Q9BXC0 1/20 0.59
CYP3A4 P08684 2/20 0.52
TP53 P04637 2/20 0.52
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
HCAR2 Q8TDS4 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
DDO Q99489 1/20 0.47
TTR P02766 1/20 0.46
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30269665 1.00 TPMT (0.70) TPMTHCAR1CYP3A4TP53KDM4E
Hydrochloric Acid SCHEMBL3779663 0.98 TPMT (0.67) TPMTHCAR1CYP3A4TP53KDM4E
SCHEMBL7189753 0.84 CYP3A4 (0.55) TPMTHCAR1CYP3A4TP53KDM4E
SCHEMBL28214359 0.83 TPMT (1.00) TPMTHCAR1TP53KDM4EALDH1A1
SCHEMBL2820215 0.83 KDM4E (0.56) TPMTTP53KDM4EALDH1A1LMNA
SCHEMBL223304 0.83 KDM4E (0.56) TPMTTP53KDM4EALDH1A1LMNA
SCHEMBL69625 0.83 TPMT (0.89) TPMTHCAR1TP53KDM4EALDH1A1
SCHEMBL109155 0.83 KDM4E (0.56) TPMTHCAR1TP53KDM4EALDH1A1
SCHEMBL23699 0.83 TPMT (1.00) TPMTHCAR1TP53KDM4EALDH1A1
Hydrochloric Acid SCHEMBL9311860 0.80 KDM4E (0.54) TPMTTP53KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459988-B High-modulus carbon fiber nylon composite material and preparation method thereof 烟台奥森制动材料有限公司 2024-09-20 CN claimed
CN-118459988-A High-modulus carbon fiber nylon composite material and preparation method thereof 烟台奥森制动材料有限公司 2024-08-09 CN claimed
EP-2890800-B1 CONTINUOUS BIOTRANSFORMATION OF SUBSTITUTED AROMATIC CARBOXYLIC ACIDS TO THEIR CORRESPONDING ALDEHYDES AND ALCOHOLS PRIVI BIOTECHNOLOGIES PVT LTD (IN) 2020-12-16 EP claimed
US-10017797-B2 Continuous biotransformation of substituted aromatic carboxylic acids to their selective aldehydes and alcohols PRIVI BIOTECHNOLOGIES PRIVATE LIMITED (IN) 2018-07-10 US claimed
US-20150252397-A1 CONTINUOUS BIOTRANSFORMATION OF SUBSTITUTED AROMATIC CARBOXYLIC ACIDS TO THEIR SELECTIVE ALDEHYDES AND ALCOHOLS PRIVI BIOTECHNOLOGIES PRIVATE LIMITED (IN) 2015-09-10 US claimed
EP-2890800-A2 CONTINUOUS BIOTRANSFORMATION OF SUBSTITUTED AROMATIC CARBOXYLIC ACIDS TO THEIR SELECTIVE ALDEHYDES AND ALCOHOLS Privi Biotechnologies Pvt. Ltd. (IN) 2015-07-08 EP claimed
WO-2014045299-A2 CONTINUOUS BIOTRANSFORMATION OF SUBSTITUTED AROMATIC CARBOXYLIC ACIDS TO THEIR SELECTIVE ALDEHYDES AND ALCOHOLS PRIVI BIOTECHNOLOGIES PRIVATE LIMITED (IN) 2014-03-27 WO claimed
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-08-19 US disclosed
CN-118459988-B High-modulus carbon fiber nylon composite material and preparation method thereof 烟台奥森制动材料有限公司 2024-09-20 CN disclosed
CN-118459988-A High-modulus carbon fiber nylon composite material and preparation method thereof 烟台奥森制动材料有限公司 2024-08-09 CN disclosed
CN-114796204-B Application of ansa triene compounds in antiviral infection medicines and preparation method thereof 中国人民解放军海军军医大学 2024-07-16 CN disclosed
CN-116354837-A Preparation method of 3, 5-diamine benzoic acid 江苏聚由新材料科技有限公司 2023-06-30 CN disclosed
US-20230099912-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-03-30 US disclosed
EP-0831845-A4 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS ELIZANOR BIOPHARMACEUTICALS IN (US) 1998-12-02 EP disclosed
EP-0831845-A1 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS Elizanor Biopharmaceuticals, Inc. (US) 1998-04-01 EP disclosed
EP-0603650-B1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AG (DE) 1997-04-02 EP disclosed
WO-1996040156-A1 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS ELIZANOR BIOPHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
US-5516805-A 3,5-substituted aminobenzoylguanidines, their use as a medicament or diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
EP-0603650-A1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-29 EP disclosed
US-4104049-A Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A TPMT 944/4885HCAR1 1903/4885CYP3A4 1357/4885
US-20230099912-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF JAK2, STAT3, STAT5A TPMT 944/4885HCAR1 1903/4885CYP3A4 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.